Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer

Low response rates and immune-related adverse events limit the remarkable impact of cancer immunotherapy. To improve clinical outcomes, preclinical studies have shown that combining immunotherapies with N-terminal Hsp90 inhibitors resulted in improved efficacy, even though induction of an extensive...

Descripción completa

Detalles Bibliográficos
Autores principales: Eisa, Nada H., Crowley, Vincent M., Elahi, Asif, Kommalapati, Vamsi Krishna, Serwetnyk, Michael A., Llbiyi, Taoufik, Lu, Sumin, Kainth, Kashish, Jilani, Yasmeen, Marasco, Daniela, El Andaloussi, Abdeljabar, Lee, Sukyeong, Tsai, Francis T.F., Rodriguez, Paulo C., Munn, David, Celis, Esteban, Korkaya, Hasan, Debbab, Abdessamad, Blagg, Brian, Chadli, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663837/
https://www.ncbi.nlm.nih.gov/pubmed/38025772
http://dx.doi.org/10.1016/j.isci.2023.108308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663837/
https://www.ncbi.nlm.nih.gov/pubmed/38025772
http://dx.doi.org/10.1016/j.isci.2023.108308

Ejemplares similares